Principal Financial Group Inc Recursion Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

$160 Billion
Q2 2024

A detailed history of Principal Financial Group Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 35,439 shares of RXRX stock, worth $247,364. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,439

Previous 397,654 91.09%

Holding current value

$247,364

Previous $3.96 Million 93.31%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$7.35 - $10.05 $2.66 Million - $3.64 Million	-362,215 Reduced 91.09%	35,439 $265,000
Q1 2024 Apr 29, 2024	SELL	$9.13 - $15.52 $2.61 Million - $4.44 Million	-285,954 Reduced 41.83%	397,654 $3.96 Million
Q4 2023 Feb 07, 2024	BUY	$5.09 - $10.79 $194,096 - $411,455	38,133 Added 5.91%	683,608 $6.74 Million
Q3 2023 Nov 02, 2023	BUY	$6.59 - $15.86 $3.98 Million - $9.59 Million	604,618 Added 1479.84%	645,475 $4.94 Million
Q2 2023 Aug 07, 2023	BUY	$4.56 - $9.94 $8,718 - $19,005	1,912 Added 4.91%	40,857 $305,000
Q1 2023 May 09, 2023	BUY	$6.42 - $9.64 $28,646 - $43,013	4,462 Added 12.94%	38,945 $259,000
Q4 2022 Feb 09, 2023	BUY	$7.16 - $12.7 $11,477 - $20,358	1,603 Added 4.88%	34,483 $265,000
Q3 2022 Nov 09, 2022	BUY	$7.83 - $13.6 $52,468 - $91,133	6,701 Added 25.6%	32,880 $350,000
Q2 2022 Aug 10, 2022	SELL	$5.04 - $9.26 $45,455 - $83,515	-9,019 Reduced 25.62%	26,179 $213,000
Q1 2022 May 09, 2022	SELL	$6.16 - $18.03 $1,681 - $4,922	-273 Reduced 0.77%	35,198 $252,000
Q4 2021 Feb 09, 2022	BUY	$16.14 - $21.86 $572,501 - $775,396	35,471 New	35,471 $608,000

Others Institutions Holding RXRX

# of Institutions

285

Shares Held

236M

Call Options Held

972K

Put Options Held

2.4M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.26B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Recursion Pharmaceuticals, Inc. Transaction History